🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06037356
Recruiting Not applicable

PUL vs TURP in BPH Patients With Urinary Retention

NCT06037356 · tracked via the Priya Life Science China tracker
Sponsor
Queen Mary Hospital, Hong Kong
Phase
Not applicable
Started
2025-01-01
Last updated
2025-07-24

Condition(s) studied

BPH With Urinary Obstruction

Investigational drug(s) / intervention(s)

Prostatic Urethral LiftTURP

Prostatic Urethral Lift: Prostatic urethral lift uses permanent implants to retract the prostate lobes away from the prostate urethra to allow unobstructed passage of urine. These implants are made of Nitinol, non-absorbable monofilament suture material (Poly Ethylene Terephthalate), Stainless Steel

TURP: Using monopolar or bipolar loop diathermy via cystoscopy, excess prostate tissue is resected piecemeal to remove obstruction to the prostatic urethra due to BPH

Study summary

The study will be a prospective, randomized controlled trial comparing prostatic urethral lift (PUL) versus transurethral resection of prostate (TURP) in benign prostate hyperplasia (BPH) patients with urinary retention. The primary objective of this study is to compare the catheter-free rates of PUL vs TURP. Secondary objectives include comparison of complications rates, cost effectiveness, patient satisfactory, symptom scores, quality of life measures and urodynamic parameters.

Eligibility

Sex
MALE
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male patients * age \>40 years old * urinary retention who failed trial without catheter Exclusion Criteria: * Inability to provide consent OR no guardians or relatives to help provide consent on patient's behalf * Active urinary tract infection * Previous surgical treatment for benign prostatic hyperplasia (i.e., TURP, prostatic urethral lift, etc.) * Bladder stones * Urethral strictures or bladder neck contractures * Prostate size \>100mL * Solely obstructing median lobe * Urinary retention not due to obstruction (i.e., Bladder outflow obstruction index \<20 on urodynamic studies) * Poor detrusor contractility (maximum detrusor pressure \<20cmH2O during voiding phase) * Anticoagulant or antiplatelet agents that cannot be stopped

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Queen Mary Hospital Hong Kong China Recruiting

More Queen Mary Hospital, Hong Kong trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06037356 on ClinicalTrials.gov ↗ ← All trials in China